Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on November 1, 2019, for the month of November 2019. The report serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the company's total voting rights and capital structure.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details as of October 31, 2019:
- Issued Share Capital: 5,382,422,661 Ordinary Shares of 25 pence each.
- Treasury Shares: 393,505,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,988,916,711.
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It provides a static snapshot of the share capital and voting rights as of October 31, 2019, intended for use by shareholders to calculate notification thresholds under FCA rules.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, outlook, risk factors, contingencies, or unusual items. Its sole purpose is regulatory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,988,916,711) against the latest annual report to ensure consistency for ownership threshold calculations.
- Confirm the number of shares held in Treasury (393,505,950) to understand the difference between issued capital and outstanding voting shares.
- Note that this filing does not contain financial results; investors should refer to Form 20-F or quarterly earnings releases for financial metrics.